One research hypothesizes that Tumor Treating Fields (TTFields), approved in combination with adjuvant temozolomide chemotherapy for newly diagnosed glioblastoma (GBM) patients, induced a significant improvement in overall survival after AIM2 and cGAS activation [70]. This evidence concerns the gene AIM2 and glioblastoma.